Emerging role of oncolytic viruses and stem cells in gene therapy: Should they be integrated?
- PMID: 35351608
- DOI: 10.1016/j.drudis.2022.03.016
Emerging role of oncolytic viruses and stem cells in gene therapy: Should they be integrated?
Abstract
Recombinant virus-based transgene therapy has shown promising results in solid tumors. Oncolytic virotherapy is a research hotspot because of its additional immunostimulatory effects. However, metastatic malignancies require systemic virotherapy, which necessitates the use of safe and effective vehicles for drug delivery. Mesenchymal stem cells (MSCs) are good carriers because of their tumor-tropic and immune-evasive capabilities. We collated published results from pre-clinical and clinical trials to support the use of MSCs as Trojan horses for the systemic administration of recombinant viruses, with a focus on glioblastoma. The generation of modified MSCs harboring recombinant viruses could expedite bench-to-bedside transformation.
Keywords: Gene therapy; Glioma; Mesenchymal stem cells; Oncolytic viruses; Targeted delivery.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources